The current results were based on 95 cases, of which 90 cases of COVID-19 were observed in the group that received the placebo compared to five cases observed in the group that was administered the candidate, called mRNA-1273.
This is a developing story. Leading up to the final analysis, Moderna expects the point estimate for vaccine efficacy may change.
The Massachusetts-based company said it plans to apply for emergency use authorization in the United States in the coming weeks and also submit authorization applications to global regulatory agencies.More news: Sia announces upcoming debut feature-inspired album
Pfizer's vaccine, on the other hand, needs to be stored in deep-freezer conditions which could complicate supply chain logistics, particularly in less developed countries.
This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.
This announcement followed announcements by USA giant Pfizer and Germany's BioNTech who said their vaccine, was found to be more than 90 per cent effective. "This includes more than 6,000 participants who identify as Hispanic or LatinX, and more than 3,000 participants who identify as Black or African American".
"The stability testing for (Moderna's) vaccine is an ongoing process", Hepburn said.More news: Post-Brexit talks hit new delay after Barnier official gets COVID-19
mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA vaccine encoding for a prefusion stabilized form of the Spike (S) protein. mRNA-1273 is one of 20 "Front Runner" candidates among the more than 300 COVID-19 therapeutics included in GEN's updated "COVID-19 Drug & Vaccine Candidate Tracker".
There were 11 people who fell severely ill, all of whom were in the placebo group. The majority of adverse events were mild or moderate in severity.
New York, Nov 16 (IANS) Moderna's Covid vaccine, which has shown 94 per cent efficacy, "remains stable at 2 to 8 degrees C (36 to 46 degrees F), the temperature of a standard home or medical refrigerator, for 30 days, the company said on Monday, sending waves of relief through the medical community".
After the first dose, about three percent of people had injection site pain classed as severe.More news: Will Smith and Janet Hubert end long-running dispute in emotional reunion